Praxis Precision Medicines, Inc. $PRAX Stock Acquired by Royce & Associates LP

Royce & Associates LP grew its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 93.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,675 shares of the company’s stock after acquiring an additional 6,131 shares during the quarter. Royce & Associates LP’s holdings in Praxis Precision Medicines were worth $3,691,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in PRAX. GAMMA Investing LLC boosted its stake in Praxis Precision Medicines by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock worth $111,000 after purchasing an additional 31 shares during the last quarter. KBC Group NV raised its position in shares of Praxis Precision Medicines by 5.8% in the first quarter. KBC Group NV now owns 715 shares of the company’s stock valued at $230,000 after buying an additional 39 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Praxis Precision Medicines by 0.9% in the third quarter. Nisa Investment Advisors LLC now owns 6,167 shares of the company’s stock valued at $1,796,000 after buying an additional 56 shares during the last quarter. Eagle Bay Advisors LLC lifted its stake in shares of Praxis Precision Medicines by 11.3% in the third quarter. Eagle Bay Advisors LLC now owns 1,064 shares of the company’s stock worth $310,000 after buying an additional 108 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Praxis Precision Medicines in the second quarter worth about $38,000. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on PRAX shares. The Goldman Sachs Group reaffirmed a “buy” rating and set a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Raymond James Financial reissued a “strong-buy” rating and issued a $945.00 target price on shares of Praxis Precision Medicines in a research note on Monday, August 17th. BTIG Research restated a “buy” rating and set a $826.00 target price on shares of Praxis Precision Medicines in a report on Monday, November 9th. UBS Group started coverage on Praxis Precision Medicines in a research report on Wednesday, October 14th. They set a “buy” rating and a $706.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Praxis Precision Medicines in a research note on Monday, August 24th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $656.42.

View Our Latest Report on Praxis Precision Medicines

Praxis Precision Medicines Stock Up 0.0%

NASDAQ:PRAX opened at $305.19 on Thursday. Praxis Precision Medicines, Inc. has a 52 week low of $160.11 and a 52 week high of $392.70. The company has a market capitalization of $8.53 billion, a P/E ratio of -23.84 and a beta of 2.85. The stock’s fifty day moving average is $287.32 and its two-hundred day moving average is $314.29.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.54) by $0.31. Sell-side analysts anticipate that Praxis Precision Medicines, Inc. will post -13.72 earnings per share for the current fiscal year.

Praxis Precision Medicines Company Profile

(Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

See Also

Institutional Ownership by Quarter for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.